Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  

Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials

Yasmin et al., PLOS ONE, doi:10.1371/journal.pone.0266245 (meta analysis)
Yasmin et al., Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized.., PLOS ONE, doi:10.1371/journal.pone.0266245 (meta analysis)
Apr 2022   Source   PDF  
  All Studies   Meta
Meta analysis of 5 colchicine RCTs (currently there are 24 RCTs) finding that treatment significantly reduced COVID-19 severity.
Currently there are 48 colchicine studies and meta analysis shows:
Mortality33% lower [21‑43%]
Ventilation29% lower [-15‑56%]
ICU admission25% lower [3‑43%]
Hospitalization17% lower [8‑25%]
Cases9% more [-6‑27%]
Yasmin et al., 5 Apr 2022, peer-reviewed, 9 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials
Farah Yasmin, Hala Najeeb, Abdul Moeed, Wardah Hassan, Mahima Khatri, Muhammad Sohaib Asghar, Ahmed Kunwer Naveed, Waqas Ullah, Salim Surani
PLOS ONE, doi:10.1371/journal.pone.0266245
Background Colchicine has been used an effective anti-inflammatory drug to treat gout diseases. Owing to its pharmacodynamic of inhibiting interleukins, it has been repurposed to target the cytokine storm post-SARS-CoV-2 invasion. The goal of this meta-analysis was to evaluate the safety profile of colchicine in COVID-19 patients using the gold-standard randomised-control trials. Methods Electronic databases (Pubmed, Google Scholar, and Cochrane) were systematically searched until June 2021 and RCTs were extracted. Outcomes of interest included allcause mortality, COVID-19 severity, mechanical ventilation, C-reactive protein and D-dimer levels. Using a random-effects model, dichotomous outcomes were pooled using odds ratios (OR) through the generic inverse variance formula while weighted mean differences were calculated using the Wan's method. P-values < 0.05 were considered statistically significant for all outcomes. Results A total population of 16,048 from five RCTs were included in the analysis. Of this, 7957 were randomized to colchicine, and 8091 received standard care, with an average age of 60.67 years. Colchicine was observed to significantly reduce COVID-19 severity (OR: 0.41, 95% CI [0.22, 0.76]; p = 0.005), and CRP levels (WMD: -19.99, 95% CI [-32.09, -7.89]; p = 0.001). However, there was no significant difference in D-dimer levels (WMD: 0.31, 95% CI [-0.61, 1.23]; p = 0.51), mechanical ventilation (OR: 0.42, 95% CI [0.17, 1.03]; p = 0.06; I 2 = 74%) and all-cause mortality (OR: 0.98, 95% CI [0.83, 1.16]; p = 0.84) among patients receiving colchicine or standard care.
Ali, Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19, Journal of Medical Virology, doi:10.1002/jmv.26097
Bikdeli, Madhavan, Jimenez, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up, J Am Coll Cardiol. Published, doi:10.1016/j.jacc.2020.04.031
Brunetti, Diawara, Tsai, Firestein, Nahass et al., Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19, Journal of clinical medicine, doi:10.3390/jcm9092961
Covid- ; Mehta, Mcauley, Brown, Sanchez, Tattersall et al., consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736%2820%2930628-0
Cronstein, Molad, Reibman, Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils, J Clin Invest, doi:10.1172/JCI118147
Deftereos, Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2020.13136
Della-Torre, Campochiaro, Cavalli, Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218122
Della-Torre, Della-Torre, Kusanovic, Treating COVID-19 with colchicine in community healthcare setting, Clin Immunol, doi:10.1016/j.clim.2020.108490
Fajgenbaum, June, Cytokine Storm, N. Engl. J. Med, doi:10.1056/NEJMra2026131
Ferro, Elefante, Baldini, COVID-19: the new challenge for rheumatologists, Clin Exp Rheumatol
Greber, Signalling in viral entry, Cell Mol. Life Sci, doi:10.1007/s00018-002-8453-3
Guan, Clinical Characteristics of Coronavirus Disease 2019 in China, N. Engl. J. Med, doi:10.1056/NEJMoa2002032
Gupta, Zhao, Evans, The stimulation of thrombosis by hypoxia, Thromb Res, doi:10.1016/j.thromres.2019.07.013
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin Exp Pharmacol Physiol, doi:10.1111/1440-1681.13488
Higgins, Thompson, Deeks, Altman, Measuring inconsistency in metaanalyses, British Medical Journal, doi:10.1136/bmj.327.7414.557
Landray, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, medRxiv, doi:10.1101/2021.05.18.21257267
Le, FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome, Oncologist, doi:10.1634/theoncologist.2018-0028
Leung, Hui, Kraus, Colchicine-Update on mechanisms of action and therapeutic uses, Seminars in Arthritis and Rheumatism, doi:10.1016/j.semarthrit.2015.06.013
Li, Liu, Mao, Predictive values of neutrophil to lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis, Crit Care, doi:10.1186/s13054-020-03374-8
Liberati, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, doi:10.1136/bmj.b2700
Lopes, Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455
Mareev, Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study, Kardiologiya, doi:10.18087/cardio.2021.2.n1560
Marnell, Mold, Clos, C-reactive protein: ligands, receptors, and role in inflammation, Clin Immunol, doi:10.1016/j.clim.2005.08.004
Martinon, Pe ´trilli, Mayor, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature, doi:10.1038/nature04516
Miller, Becker, Grenfell, Metcalf, Disease and healthcare burden of COVID-19 in the United States, Nat. Med, doi:10.1038/s41591-020-0952-y
Notley, Tinlin, Sawyer, Begbie, Lillicrap, The factor VIII acute phase response requires the participation of NFκB and C/EBP, Thrombosis and Haemostasis
Parra-Medina, Sarmiento-Monroy, Rojas-Villarraga, Garavito, Montealegre-Gomez et al., Colchicine as a possible therapeutic option in COVID-19 infection, Clin. Rheumatol, doi:10.1007/s10067-020-05247-5
Qin, Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clin. Infect. Dis, doi:10.1093/cid/ciaa248
Reyes, Hu, Teperman, Anti-inflammatory therapy for COVID-19 infection: the case for colchicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219174
Reyes, Hu, Teperman, Muskardin, Tardif et al., Anti-inflammatory therapy for COVID-19 infection: the case for colchicine, Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2020-219174
Scarsi, Piantoni, Colombo, Airo, Richini et al., Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep, doi:10.1007/s40495-020-00225-6
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep, doi:10.1007/s40495-020-00225-6
Sproston, Ashworth, Role of C-reactive protein at sites of inflammation and infection, Frontiers in Immunology, doi:10.3389/fimmu.2018.00754
Sterne, RoB 2: A revised tool for assessing risk of bias in randomised trials, BMJ, doi:10.1136/bmj.l4898
Tardif, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir. Med, doi:10.1016/S2213-2600%2821%2900222-8
Tayer-Shifman, Ben-Chetrit, Familial Mediterranean fever and hypercoagulability, Mediterranean journal of hematology and infectious diseases, doi:10.4084/MJHID.2011.017
Turk, Turk, Malkan, Haznedaroglu, Three critical clinicobiological phases of the human SARS-associated coronavirus infections, Eur. Rev. Med. Pharmacol. Sci, doi:10.26355/eurrev%5F202008%5F22660
Wan, Wang, Liu, Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC Med. Res. Methodol, doi:10.1186/1471-2288-14-135
Wang, Wu, Zhang, C-reactive protein level may predict the risk of COVID-19 aggravation, Open Forum Infect Dis, doi:10.1093/ofid/ofaa153
Yao, D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study, J. Intensive Care, doi:10.1186/s40560-020-00466-z
Zhang, Li, Shen, Chen, Qi, Rational use of tocilizumab in the treatment of novel coronavirus pneumonia, Clin Drug Investig, doi:10.1007/s40261-020-00917-3
Zhang, Wu, Li, Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105954
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736%2820%2930566-3
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop